Skip to content
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
featured-image

Press Release

RapidAI Announces New Continuing Education Credits

Leader in Cerebrovascular and Vascular Imaging Expands Clinical Learning and Development Offerings through Rapid U San Mateo, Calif. — June 8, 2021 — RapidAI, the leader in clinical learning and development for stroke, aneurysm, and other cerebrovascular and vascular conditions, today announced the availability of Continuing Education (CE) and Continuing Medical Education (CME) credits for healthcare teams through its Rapid U training and education program. The new learning modules offered through Rapid U help healthcare professionals meet ongoing clinical education requirements and earn credits to keep their licenses current while simultaneously becoming proficient with RapidAI products and effectively integrating them into their site’s workflow “Today’s healthcare practitioners need hands-on training and education that seamlessly fits into their workloads,” Don Listwin, CEO of RapidAI, said. “By offering courses with CE and CME credits through Rapid U, we’re proud to make the program a convenient one-stop resource for entire medical teams to expand their professional knowledge and master their usage of RapidAI products to positively impact patient outcomes.” Free to all RapidAI customers, Rapid U provides access to self-paced online courses on how to use RapidAI technology; live virtual and onsite training led by physicians, nurses, stroke coordinators and technologists; and performance-support content including case studies, publications, quick reference guides and more. Rapid U training and education content is customized for hospitals and health systems to support their workflows, and each user’s experience is tailored to suit their specific function through a series of role-based learning paths. “Rapid U has evolved into a comprehensive clinical learning and development resource customized for a site’s specific needs and the individual user’s role,” Haig Soghigian, VP of Global Services at RapidAI, said. “Not only are medical teams provided with easy access to courses that help them meet their continuing education requirements, but they’re also expanding their knowledge of the vascular and cerebrovascular conditions that face their patients every single day.” CE and CME credits are offered through a combination of online courses that can be accessed from the Rapid U Learning Management System (LMS) and live, virtual training led by expert instructors. CE credits are currently available for radiologic technologists. A limited number of CME credits for physicians and CE credits for nurses, stroke coordinators and paramedics are also being offered, with expanded availability beginning in July. For more information or to get started, please visit https://www.rapidai.com/continuing-education .
featured-image

Press Release

RapidAI Unveils Prehospital Solution

Directly enhances collaboration between Emergency Medical Services (EMS) and hospital care teams San Mateo, Calif. — May 20, 2021 — RapidAI, leading the next evolution of clinical decision making and workflow, today announced the launch of their Rapid prehospital workflow solution for stroke, which optimizes coordination between EMS providers and hospital care teams to help deliver patients the best care as fast as possible. Recent studies show that every ten-minute delay in the hospital resulted in eight weeks of healthy life lost. Furthermore, every one-hour delay in the hospital resulted in 11 months of healthy life lost. With the new prehospital solution, RapidAI is helping care teams give healthy life back to patients by embracing the value of smart workflows. By streamlining communication and synchronizing patient data, the RapidAI prehospital workflow apps, help both EMS and hospitals strengthen patient care from initial intake and assessment all the way to discharge and follow up. EMS teams using the prehospital workflow mobile app can follow a standardized stroke protocol and streamline data collection to help get patients to an appropriate hospital. Meanwhile, the hospital stroke team can use the prehospital workflow app to more easily collaborate with EMS in route by receiving and reviewing patient data, and starting the stroke workflow. Laying the foundation for quicker, better care throughout every stage of the patient journey, the Rapid prehospital solution enables EMS providers to: Establish and follow a standardized stroke protocol Select appropriate hospitals for patient care Share critical patient data with hospitals and specialists in real time Receive feedback on patient outcomes “Surviving a stroke can no longer be left to chance. Patients should not suffer unnecessarily because of practice variability, inadequate communication, and antiquated point-of-entry protocols for stroke,” said Ryan A. McTaggart, MD, Director of Interventional Neuroradiology at Rhode Island Hospital. “The RapidAI prehospital app is a groundbreaking tool created and designed by EMS professionals and specialized stroke teams to eliminate bottlenecks in care so patients can return home to their loved ones without disability. It’s the holy grail for prehospital and in-hospital stroke teams eager to do the best they can for these patients.” “The prehospital solution is a critical piece of our mission to revolutionize patient care for neurovascular and vascular diseases,” said Don Listwin, President and CEO of RapidAI. “Inefficient processes have serious consequences, and we’re thrilled to lead the charge on shifting this paradigm for good. We’ll quickly evolve our prehospital solution beyond stroke to include STEMI and trauma. After all, a stronger workflow between EMS and care teams results in stronger patient care all around." For more information about the new solution, please visit: https://www.rapidai.com/rapid-prehospital .
featured-image

Press Release

New RapidAI Insights Improves Hospital Understanding of Stroke Business

New RapidAI Insights Improves Hospitals’ Understanding of Their Stroke Businesses, as Well as Patient Workflow and Outcomes San Mateo, Calif. — May 6, 2021 — RapidAI, the leader in advanced cerebrovascular imaging, today announced the expansion of RapidAI Insights, a unique analytics solution that uses Rapid® scan, treatment, and outcome data to enable hospitals and hospital systems to make more informed business decisions, reduce costs across sites, and improve patient outcomes. New and enhanced reports give a deeper understanding of patient journeys and outcomes, team workflow and communication, as well as executive purview into the comprehensive metrics of a stroke practice. RapidAI Insights delivers a growing portfolio of analytic reports for multi-site systems and referral networks. RapidAI Insights empowers users to standardize and improve processes for stroke care, increase usage, and enable easier data monitoring and security, all while optimizing operational efficiencies. “Over the last three years stroke care has evolved very quickly. While RapidAI is laser focused on patient outcomes, we have also expanded our offerings to help our hospital and hospital system clients save time, and better understand and improve their stroke practices overall,” said Don Listwin, CEO of RapidAI. “In 2020 we launched RapidAI Insights, the first comprehensive stroke analytics solution. Now we have built on that innovation with analytics and reports that reveal critical new metrics of care, workflow, outcomes and efficiency." Expanded RapidAI Insights Reports Patient Journey and Outcomes Report offers a detailed view into patients’ journeys and clinical outcomes to help drive stroke protocol improvements. Executive Report offers an information-rich summary of site-specific information across systems looking to monitor RapidAI system adoption, optimize operational efficiencies, reduce stroke-related costs, and drive better clinical outcomes. Workflow and Communication Report provides hospital sites and systems with reporting and analysis of Rapid workflow product usage to measure the impact on time to treatment, identify trends in workflow and optimize user engagement with the Rapid Mobile App and Web App. To learn more about RapidAI Insights, visit rapidai.com/rapidai-insights .
featured-image

Press Release

RapidAI Named Partner for Stroke Certification in Latin America

Partnership will Expand the Availability of AI-Powered Stroke Imaging Throughout Latin America San Mateo, Calif. — April 8, 2021 — RapidAI, the leader in advanced cerebrovascular imaging, today announced it has partnered with the World Stroke Organization (WSO) and Sociedad Iberoamericana de Enfermedad Cerebrovascular (SIECV) to become the exclusive neuroimaging partner for their new Stroke Center Certification Program in Latin America. Within the cross-continent initiative, RapidAI will provide a combination of its comprehensive AI-powered Rapid® stroke imaging platform and its unique Rapid U stroke training and certification program to hospitals across Latin American. The new Stroke Center Certification Program in Latin America was created by WSO President-Elect Dr. Sheila Martins to increase the quality and safety of stroke treatment in Latin America and improve patient outcomes. Per the WSO, the certification of stroke centers is critical to ensure that hospitals implement and monitor all priority strategies that change the natural history of stroke, reducing mortality and disability. It is a great opportunity for continuous improvement of services and qualification of comprehensive care in the region. The program aims to certify more than 100 advanced and essential stroke centers across Latin America, in the next year. “This is the most exciting time in history to be working in stroke care, because we have the tools, the program, and now the exclusive partnerships to bring world-class stroke education and technology to stroke centers throughout Latin America,” said Dr. Sheila Martins, President-elect of the WSO, founder of the Brazilian Stroke Network, Neurology Professor of Universidade Federal do Rio Grande do Sul and Chief of Neurology and Neurosurgery Service at Hospital Moinhos de Vento. “We are incredibly grateful to have RapidAI on board as our advanced medical imaging partner. Their clinically proven technology and training has been instrumental in expanding and improving stroke care internationally. Further, their understanding of the region will contribute to the program’s success and growth.” Already in over 60 countries, Rapid is the most widely used advanced cerebrovascular imaging platform for patient care, research and clinical trials across the globe. “RapidAI is committed to improving stroke care on a global level, and we are delighted that this exclusive partnership with the WSO and SIECV enables us to bring AI-powered stroke imaging to more hospitals and more patients across Latin America,” said Dr. Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of RapidAI. “Ever since our research helped significantly expand stroke care guidelines in 2018, the worldwide need for Rapid imaging has continued to accelerate. We look forward to contributing to this program’s success and using it as a blueprint to facilitate similar WSO initiatives around the world.” To learn more about the WSO and SIECV Stroke Center Certification Program in Latin America, visit www.globalstrokealliance.com.
featured-image

Press Release

RapidAI Breaks New Ground

The company experienced record-shattering 2020 milestones as well as an expansion of its scope into the larger vascular market San Mateo, Calif. — February 24, 2021 — RapidAI, the leader in advanced cerebrovascular imaging, today announced record-shattering 2020 milestones for the company and industry, as well as an expansion of its scope into the larger vascular market. As RapidAI momentum built around the world, in addition to new products, partnerships, and awards, 2020 saw the company expand from stroke to aneurysm and lay the groundwork for other vascular diseases, both acute and non-acute. The RapidAI footprint grew to over 60 countries, with its technology utilized in over 1,800 hospitals. RapidAI offers the most-widely used advanced cerebrovascular imaging products for patient care, research, and clinical trials across the globe. RapidAI clinical products help save lives. In 2020, RapidAI workflow and messaging technologies helped stroke teams save time, and RapidAI analytics and business intelligence products began helping stroke networks reduce costs and improve patient outcomes. “2020 was such a challenging year for so many around the world, it’s gratifying that our growth and success meant many more lives saved from cerebrovascular disease across dozens of countries,” said Don Listwin, CEO of RapidAI. “Last year we expanded our global footprint, we introduced important new technologies, we helped hospitals understand their businesses better, we made our first strategic acquisition, and we expanded our scope from stroke to include other vascular illnesses, such as aneurysm and pulmonary embolism. With 2020 in the books, we join the world in looking toward a brighter 2021.” RapidAI Growth: Building on years of profitability, announced a $25 million Series B, to accelerate strategic growth initiatives around the world Acquired EndoVantage and expanded scope to address aneurysm Expanded to 60 countries, including Australia and Argentina Worldwide adoption of the Rapid® platform reached 1,800 hospitals Processed more than 1,000,000 stroke imaging scans in 2020 alone, more than a 1,900% increase over 2017 Achieved greater than 100% year-over-year increase in patients scanned Became RapidAI. The company that leads AI-enhanced stroke imaging around the globe, embraced the future with a new brand and website, RapidAI.com Rapid LVO became one of the first software products to qualify for the New Technology Add-on Payment (NTAP), a significant advancement in stroke care reimbursement Launched the RapidAI Technology Partner Program Partnered with Penumbra, for expansion into pulmonary embolism “RapidAI’s credibility can be assessed from the fact that their solutions are used by over 1,800 hospitals in over 60 countries, and them being profitable since their founding year – an extremely rare occurrence in the imaging AI sector,” said Parth Shah, Senior Research Analyst at Frost & Sullivan. “Not resting on their laurels, in 2020 RapidAI added features to their solutions to address the workflow for stroke interventions, thus providing an end-to-end capability from triaging to intervention. Ultimately this will result in even faster time to treatment, further enhancing patient outcomes and reducing long-term costs.” RapidAI Innovation: Rapid ASPECTS received Food and Drug Administration (FDA) clearance as the first neuroimaging analysis device in the CADx (Computer-Assisted Diagnostic software) category. Rapid ASPECTS is the only neuroimaging product shown to improve physicians’ interpretations of Non-Contrast CT (NCCT) scans using a standardized ASPECT score RapidAI offered Rapid Aneurysm, a comprehensive aneurysm management platform Rapid LVO received FDA clearance for detecting suspected Large Vessel Occlusions. Rapid LVO helps physicians speed up triage or transfer decision-making Introduced RapidAI Insights, a valuable solution for multi-site systems and referral networks looking to standardize stroke care processes and optimize operational efficiencies that help to reduce costs across sites, while simultaneously improving patient outcomes and saving more lives Launched the Rapid Web App, which offers stroke teams a convenient way to view notifications of new cases, preview Rapid results and source files, and enable workflow communications among team members via their desktop or laptop RapidAI Awards: RapidAI received the 2020 Global Company of the Year Award from Frost & Sullivan RapidAI won a Minnie. AuntMinnie.com named RapidAI The Best New Radiology Vendor of 2020 RapidAI was awarded the 2020 Global Growth, Innovation & Leadership Frost Radar Award
featured-image

Press Release

RapidAI Acclaimed by Frost & Sullivan for AI-powered Stroke Platform

The technology used in the Rapid platform is highly unique and scalable and can deliver exceptional cost efficiencies to hospitals of all sizes Santa Clara, Calif. — February 10, 2021 — Based on its recent analysis of the global intelligent imaging analysis systems market, Frost & Sullivan recognizes RapidAI with the 2020 Global Growth, Innovation & Leadership Frost Radar Award for its artificial intelligence (AI) and machine learning enabled stroke platform. The solution is a one-stop-shop for healthcare providers looking to standardize stroke and aneurysm care and improve patient health outcomes. View the full Frost & Sullivan report - no subscription required. The Growth Innovation Leadership (GIL) best practice award recognition is bestowed upon companies that are market leaders at the forefront of innovation. These companies consolidate or grow their leadership position by continually innovating and creating new products and solutions that serve the evolving needs of the customer base. In addition, these companies are also best positioned to expand the market by strategically broadening their product portfolio. “RapidAI’s platform has revolutionized stroke and aneurysm care by providing clinicians with clinically validated insights aimed at improving patient care and outcomes,” said Neeraj Nitin Jadhav, Senior Research Analyst at Frost & Sullivan. ”While RapidAI is a showcase of technology innovation and swift growth, it also earned the 2020 Global Growth, Innovation & Leadership Frost Radar Award for its strategic path to continue to shape the intelligent imaging market.” A highly modular platform, Rapid® comprises numerous solutions such as Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, Rapid ICH, Rapid MRI, RapidAI Insights, and SurgicalPreview. Rapid ICH quickly triages NCCT scans to identify suspected intracranial hemorrhages (ICH), Rapid ASPECTS automatically identifies regions of the brain and generates a score to help physicians assess patient eligibility for thrombectomy. Rapid CTA and Rapid LVO enable physicians to identify suspected large vessel occlusions (LVOs), and Rapid CTP can help assess salvageable brain tissue through quantified and color-coded CT perfusions maps. SurgicalPreview provides comprehensive cerebral aneurysm management, automating the workflow from the initial assessment to growth monitoring and treatment planning. The Rapid Mobile and Web apps enable streamlined communication and workflow across treatment teams and hospitals for faster treatment and decisions. All the data from the Rapid platform feeds into RapidAI Insights, a powerful analytics solution that provides metrics to help hospital sites and systems deliver standardized care and make more informed business decisions. With a run-rate of over 1 million scans processed annually, RapidAI leverages the data to improve the functionality and performance of its solutions as well as the business intelligence of its customers. The company aims to build on its technology advantage by signing strategic partnerships and acquisitions, and by investing in research and development to extend the use of the Rapid platform to other vascular diseases. As a case in point, the acquisition of EndoVantage in June 2020 has significantly cemented RapidAI’s position in the cerebral aneurysm management space. "The RapidAI platform is commercially available in more than 60 countries," noted Jadhav. "Its presence in 1,600+ hospitals across the globe and its suitability for hospitals of all sizes augurs well for its adoption among developed, developing, and emerging countries." Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. About RapidAI RapidAI is the worldwide leader in advanced cerebrovascular imaging and workflow. Based on intelligence gained over 1 million scans from more than 1,600 hospitals in over 60 countries, the Rapid® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, CBCT angiography and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, Rapid for Angio and Rapid MRI. RapidAI also offers SurgicalPreview®, a comprehensive aneurysm management platform. RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically proven, data-driven technology. With its validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day.
featured-image

Press Release

RapidAI Cleared in Argentina

Adopted by top hospitals to improve stroke imaging and care San Mateo, Calif. — February 4, 2021 — RapidAI, the leader in advanced imaging for stroke, today announced it has received registration approval and clearance from Argentina’s Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) for the Rapid imaging platform. Rapid is available to hospitals across Argentina, and already in use at Clínica La Sagrada Familia and Fleni. “Meaningful breakthroughs in stroke care do not come along that often, but Rapid’s clearance in Argentina has had immediate positive effects both for our stroke team and patients,” said Dr. Sebastián Ameriso, Jefe de Centro Integral de Neurología Vascular a Fleni. “Since employing Rapid we have increased mechanical thrombectomy by around 50% compared to the same time last year. Rapid has instantly become a critical weapon in our daily fight against the debilitating and deadly effects of stroke.” Internationally, Rapid is available in more than 60 countries, and the only clinically validated platform. Rapid is considered by many to be the gold standard for advanced cerebrovascular imaging. “The AI-powered Rapid platform facilitates faster and more accurate diagnoses in our hospital, where the triage based on the combination between MRI and CT empower the team’s therapeutic decision gaining time during a stroke to save and improve patient lives,” said Dr. Pedro Lylyk, Director del Departamento de Neurociencias Clínica La Sagrada Familia. “During Rapid implementation, in our Institution, Covid-19 struggled Argentina. Collaterally RapidAI improved our workflow to save time during the first wave of the Pandemic. Simply put, that means improved care and better results for all our patients.” RapidAI makes the most-widely used advanced cerebrovascular imaging products for patient care, research, and clinical trials across the globe. RapidAI clinical products help save lives, RapidAI workflow and messaging technologies help stroke teams save time, and RapidAI analytics and business intelligence products help stroke networks reduce costs and improve patient outcomes. “Already in use within two of Argentina’s leading stroke centers, we are proud to bring the best in AI-powered stroke imaging to Argentina,” commented Renato Cunha, Vice President of LATAM Sales and Operations at RapidAI. “This is one more important step in making RapidAI’s technology available across LATAM and the World.”
featured-image

Press Release

RapidAI Enhancing Stroke Care Across Australia

RapidAI now serves over 50 hospitals and teleradiology services in Australia. San Mateo, Calif. — January 21, 2021 — RapidAI, the leader in advanced imaging for stroke, today announced it now serves over 50 hospitals and teleradiology services in Australia. The Rapid stroke imaging platform is TGA cleared. Rapid is the first AI-powered stroke imaging solution approved in Australia. Around the world, Rapid is also the only clinically validated platform available and the gold standard for advanced cerebrovascular imaging and workflow. In addition to broad adoption across the country, Rapid is also being rolled out across the state of New South Wales (NSW). In NSW, Rapid is part of a comprehensive telehealth initiative which leverages the Rapid Mobile App to optimize workflow, communication, and expedite patient treatment throughout the state’s large comprehensive and regional community hospitals. Along with wide commercial success, RapidAI also continues to drive the research charge in Australia. The company is developing industry leading cerebrovascular imaging solutions through participation in clinical trials with 8 leading Australian hospitals and institutions. “It has been gratifying to bring RapidAI technology home to support Australian healthcare,” said Doctor Roland Bammer, Professor of Radiology and Director of the NHMRC Centre for Research Excellence in Neuroimaging at the University of Melbourne, Cofounder and CTO at RapidAI. “We have a long-standing research collaboration with Australian Stroke researchers and it is great to see this translated into clinical routine. Australia is a vast country and I am delighted to see more people having access to faster care irrespective of their postcode.” Doctor Bammer continued, “The statewide adoption in NSW alone has shown the true potential of network coordinated AI-powered stroke imaging and the resulting improvement in care. I am also excited that Monash Health, one of the largest hospital systems in Victoria, is now using Rapid. With its catchment area in the South Eastern Melbourne Metropolitan corridor, the institution reaches over two million Victorians. Access to the Rapid platform will have a considerable positive impact on the Acute Stroke care continuum for the Monash team and its patients.” RapidAI makes the most-widely used advanced cerebrovascular imaging products for patient care, research, and clinical trials across the globe. RapidAI clinical products help save lives, RapidAI workflow and messaging technologies help stroke teams save time, and RapidAI analytics and business intelligence products help stroke networks reduce costs and improve patient outcomes.
featured-image

Press Release

RapidAI Receives Global Company of the Year Award

The honor, awarded by Frost & Sullivan, is for the company's AI-powered stroke imaging and diagnosis technologies Santa Clara, Calif. — January 13, 2021 — Based on its recent analysis of the global AI-based stroke imaging and diagnosis market, Frost & Sullivan recognizes RapidAI with the 2020 Global Company of the Year Award. Its innovative and clinically-validated Rapid platform leverages AI to support almost all phases of stroke imaging workflow, from initial interpretation to final reporting. RapidAI products help perform the early identification of stroke and aneurysm using software such as Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, Rapid MRI and SurgicalPreview, to expedite treatment. View the full Frost & Sullivan report - no subscription required Rapid ICH uses AI to quickly triage NCCT scans to identify suspected intracranial hemorrhages (ICH). Rapid ASPECTS uses machine learning algorithms to automatically identify regions of the brain and generate scores to help physicians quickly assess patient eligibility for thrombectomy. Rapid CTA and Rapid LVO help physicians quickly identify suspected large vessel occlusions (LVOs) by automatically processing CT scans and delivering clear, easy-to-interpret CT angiography images. Rapid CTP enables physicians to assess salvageable brain tissue through the delivery of quantified and color-coded CT perfusions maps that identify brain regions with reduced cerebral blood flow, volume, density, and transit time. SurgicalPreview provides comprehensive cerebral aneurysm management—automating the workflow from initial assessment to growth monitoring and treatment planning. The Rapid Mobile and Web apps enable streamlined communication and workflow across treatment teams and hospitals for faster treatment and transfer decisions. On top of this RapidAI Insights is a powerful analytics solution that provides metrics to help hospital sites and systems deliver standardized care and make more informed business decisions. "RapidAI has a footprint across 1,600 hospitals in more than 60 countries. In addition to a global distribution network, the company leverages partnerships with various healthcare technology leaders such as Siemens Heathineers, Samsung Neurologica, Mobile Heartbeat, and Halo Health to grow its customer base and improve brand loyalty," said Parth Shah, Senior Research Analyst. "The company’s products make hospitals more responsive while enabling better transfer decisions for patients. As a result, RapidAI not only saves time and costs but improves long-term outcomes by enabling faster stroke interventions." RapidAI can be integrated with almost every CT and MRI manufacturer model and make. Its workflow implementation requires minimal effort, while its software platform is fully automated and works on a single virtual or physical server within the hospital firewall. The RapidAI team configures the server using remote access via a Site2Site VPN tunnel, client-based VPN connection, or portal-based connection. RapidAI’s installation and implementation teams also work with the client’s IT team to schedule and optimize upgrades. "The company’s Rapid Web App extends access into yet another user environment, offering stroke team members a convenient way to view real-time browser notifications regarding new cases and enable workflow communications via a desktop or laptop. The Rapid Mobile App is another useful tool that provides anytime-anywhere alerts and access to RapidAI results," noted Shah. "Overall, the company’s relentless focus on innovation and strategic technological acquisitions enables the development of new capabilities that will drive continuing growth and improve vascular care globally." Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration. Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact: Harley Gadomski P: 12104778469 E: harley.gadomski@frost.com About RapidAI RapidAI is the worldwide leader in advanced imaging for stroke. Based on intelligence gained from over 1,000,000 scans, from more than 1,600 hospitals in over 60 countries, the Rapid® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, and Rapid MRI. RapidAI also offers SurgicalPreview®, a comprehensive aneurysm management platform. RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically-proven, data-driven technology. With our validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day. For more information, visit RapidAI.com.
2 3 4 5 6